regulatory
confidence high
sentiment negative
materiality 0.65
Daré Bioscience gets Nasdaq bid-price deficiency notice, has until March 29, 2027 to regain compliance
Dare Bioscience, Inc.
- Nasdaq notified Daré on September 28, 2026 that DARE's closing bid price was below the $1.00 minimum for 30 consecutive business days.
- Daré has 180 calendar days, until March 29, 2027, to regain compliance under Nasdaq Listing Rule 5550(a)(2); the notice has no immediate listing effect.
- Compliance requires a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.
- If not cured, Daré may qualify for an additional 180-day period, but failure could lead to delisting and a Nasdaq Hearing Panel appeal.
- Daré said it will monitor its closing bid price and consider options to regain compliance, with no assurance it will succeed.